Company intelligence / Profile preview

EonveLab

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

EonveLab is an early-stage biotechnology company focused on developing next-generation metabolic therapies for obesity and related metabolic disorders. The company specializes in the discovery of multi-agonist peptides and small molecules targeting the GLP-1, GIP, and glucagon receptors. By leveraging advanced molecular design, EonveLab aims to create highly potent and tolerable treatments that address the global burden of metabolic disease. Their current research efforts are centered on optimizing lead candidates for transition into clinical development.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small moleculePeptides
Industry: Biotech

Beyond the preview

Go deeper on EonveLab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EonveLab.

Explore the full profile